

BSW Formulary Update – Following APC Oct 2020 meeting

Not included on the BSWformulary

- Black TLS Light  **BLACK** (in use from Oct 2020) will be used where a decision has been made by the BSW APC **not** to routinely include a product on the BSWformulary. Do not prescribe these products.
- [Omeprazole 2mg/ml and 4mg/ml powder for oral suspension \(Rosemont\)](#). These preparations (launched in 2019) have been assigned a Black Traffic Light as the APC did not consider them a cost-effective use of NHS resources for adults or for children. *Further discussion is ongoing about use of this omeprazole suspension for infants ≤12 months of age with a feeding tube in situ.*

Changes in Traffic Light Status

- [Oxybutynin](#) (all formulations) moved from Green to Amber for new patients. This is in line with the updated Over Active Bladder prescribing pathway (see below).

New and Updated Prescribing Guidelines

- **Updated - [Over Active Bladder guidelines](#)** Pathway has been updated in line with increasing evidence of long term harm from anticholinergic medicines on cognitive function. Guidance advises on ensuring correct diagnosis, suggestions for conservative management and trials of stopping medicines. Oxybutynin should not be started in primary care for OAB in new patients. Review existing patients at least 12monthly (6monthly if >75yrs). A PIL to support discussions about anticholinergic medications is available [here](#) . Formulary entries have been updated [here](#)
- **Updated – [BSW Management of Infections in Primary Care](#)**: Includes update from NICE on antimicrobial prescribing for insect bites and stings.
- **Updated – [BSW Self-monitoring of Blood Glucose in Diabetes Guidelines](#)** This guidance standardises practice across BSW. **For new initiations and meters requiring replacement, the True Metrix Air Meter which uses True Metrix test strips is considered first line.** There is no requirement for practices to switch meters unless a more costly system with complex functions such as carb-counting and bolus dosing (where these are not required) is currently being used in T2D patients. T1D patients should not be switched without oversight from DSNs.
- **Updated - [INR self-testing and self-monitoring guidance](#)** INR test strips e.g. CoaguChek, included on the formulary but **ONLY** for prescribing in line with this updated BSW guidance. This represents a change for BaNES patients only.
- **New - [Sharps Bin Prescribing on an FP10](#)** Guidance to support safe and cost-effective prescribing of waste bins for sharps and cytotoxic waste.
- **Updated – [BSW Guidance and Management of Cow's Milk Protein Allergy](#)** Comprehensive prescribing guide for managing infants with suspected CMPA. Formulary section on specialised formula milk also in development [here](#)

- **New - [Managing patients with prostate cancer on LHRH analogues during COVID](#)** Guidance to support a switch to 6 monthly Decapeptyl injections where appropriate to reduce face to face appointments. This is also cost-effective.

New additions to the BSWformulary

- **[0.02mg ethinylestradiol & 3mq drospirenone tablets](#)** (Eloine®) oral contraceptive Green TLS - Added as third line option. Slightly lower ethinylestradiol content so suitable for those patients having side-effects with higher strength preparations

Supportive information

- **[Entacapone](#)** – Information to support switching to multi-agent preparations if necessary due to shortages of entacapone.
- **[Management of perinatal mental health](#)** – AWP document useful for primary care clinicians

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net

What the BSW CCG formulary team are currently working on

- Producing a policy/pathway and prescribing criteria for use of melatonin
- Updating the Vitamin D guidance
- Updating the Vitamin B12 guidance
- Updating the domperidone guidance
- Updating the constipation guidance
- Updating the pain management documents
- Reviewing formulary position of Cox-2 inhibitors
- Position statements on various devices
- Aligning Shared Care Agreements across BSW starting with document on DMARD monitoring